Targeting the APOBEC Mutational Signature: Precision Reagents for DNA Editing Enzyme Inhibition and Cancer Evolution Research
The APOBEC3B cytidine deaminase has emerged as a critical driver of tumor mutational burden (TMB) and therapeutic resistance across multiple malignancies. As pharmaceutical development pivots toward inhibiting APOBEC-mediated mutagenesis to prevent cancer evolution and drug resistance, TarMart provides the high-fidelity enzymatic tools and orthogonal validation systems required for mechanism-based drug discovery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for APOBEC3B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | APOBEC3B Recombinant Protein (Full-length). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW ~46 kDa. HEK293 Expressed. | View APOBEC3B Products |
| Antigen (Catalytic Dead) | APOBEC3B E255Q Mutant Protein. Catalytically inactive control for mechanism studies. Endotoxin <1 EU/μg. | View APOBEC3B Products |
| Gene Delivery | APOBEC3B Promise-ORF / Lentivirus. Full-length ORF with N-terminal FLAG or GFP tags for stable cell line construction. | View APOBEC3B Products |
| Benchmark Ab | Anti-APOBEC3B Recombinant Antibody (Clone 4A7 Equivalent). Positive control for Western Blot and IHC detection. | View APOBEC3B Products |
| Validator | APOBEC3B siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View APOBEC3B Products |
| Related Target A | APOBEC3A (92% catalytic domain homology). Crucial for selectivity screening to avoid off-target immunosuppression. | View APOBEC3A Products |
| Related Target B | APOBEC3G. Retroviral restriction factor; comparator for HIV research applications. | View APOBEC3G Products |
| Related Target C | AID (AICDA). B-cell specific deaminase; essential for selectivity profiling against lymphoid targets. | View AICDA Products |
| Related Target D | UNG (Uracil DNA Glycosylase). Downstream base excision repair enzyme, highly synergistic pathway. | View UNG Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity (DNA Deamination) | Sequence-verified WT protein with validated ssDNA cytidine deamination activity; Catalytic dead E255Q mutant available as negative control. |
| Subfamily Selectivity (A3A vs A3B vs A3G) | APOBEC3A and APOBEC3B ortholog proteins with >95% purity for cross-reactivity panels; Mass spec verified identity. |
| Intracellular Target Engagement | Cell-permeable assay formats supported by Lentiviral ORF delivery systems for stable overexpression lines. |
| Conformational Stability | Optimized expression systems (HEK293/Insect) to maintain native folding and prevent aggregation. |
| Lack of Reliable Controls | Recombinant positive control antibodies and validated siRNA included for rigorous specificity checks. |
Live APOBEC3B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The APOBEC3B-driven mutational signature (TCW>TTW/TCW>TGW) is detected in >50% of breast, bladder, cervical, and lung cancers, correlating with poor prognosis and therapy resistance. The current R&D landscape is shifting from observational biomarker studies to first-in-class inhibitor development, with leading programs focusing on small-molecule active site inhibitors and allosteric modulators that specifically suppress APOBEC3B while sparing APOBEC3A-mediated antiviral immunity. Major players and specialized biotechs are shifting focus toward Small Molecules and PROTACs designed to halt this hypermutation engine. As first-generation inhibitors transition from academic research into preclinical pipelines, the next wave of R&D is targeting combination therapies—pairing APOBEC3B inhibitors with targeted therapies (like EGFR or KRAS inhibitors), PARP inhibitors, or immunotherapies to prevent the emergence of acquired drug resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic consortia, Specialized DDR Biotechs | Breast Cancer, NSCLC (TMB-high), Ovarian Cancer | Enzymatic deamination assay (Need high-purity WT and mutant proteins) |
| PROTAC / Degrader | Emerging Stealth Biotechs, Targeted protein degradation startups | Refractory Solid Tumors (Prevent resistance) | Ternary complex validation (Need sequence verified full-length proteins) |
| RNAi / ASO | Targeted Delivery Pharma, Early Discovery Programs | Metastatic Tumors, Solid Tumors (TMB reduction) | Knockdown validation (Need validated siRNA and Lentivirus ORF controls) |
| Allosteric Modulator | Preclinical Platforms | Combination with Immunotherapy | Conformational binding assay (Need full-length protein, native folding) |
| Antiviral Research | HIV research institutions | Viral restriction studies | Comparative A3B vs A3G activity panels |